Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PHVS with free AI briefings, catalyst countdowns, and dilution alerts.

PHVS · Pharvaris N.V.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$318.3M Cash on Hand
24.6mo Cash Runway
Follow PHVS by email Get an email when PHVS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PHVS, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-04-23 Deucrictibant IR NDA 66%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What PHVS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Deucrictibant Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) Phase 3 · NCT07266805 Recruiting
Deucrictibant IR Hereditary Angioedema N/A · NCT07759141 Available

Also used in these trials (approved or third-party drugs, not PHVS's own candidates): Icatibant.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PHVS holds $318.3M in cash and short-term investments and burns about $38.8M/quarter from operations, an estimated runway of 24.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PHVS files for a raise →

👥 Who Owns PHVS

Insiders 2% Institutions (168 holders) 94.5% Public and other holders 3.5%
HolderTypeShares% of sharesAs of
Wellington Management Group LLP Institution (13G, 5%+) 6,696,804 10.27% 2026-09-30
Berndt Modig
Chief Executive Officer, Director
Insider 650,000 1.00% 2026-09-17
Anne Lesage
Chief Early Development · +15,000 options
Insider 130,419 0.20% 2026-09-17
Schikan Johannes Gerardus Christiaan Pet
Director · +34,200 options
Insider 115,167 0.18% 2026-09-22
David W. Nassif
CFO / CLO
Insider 113,800 0.17% 2026-09-21
Peng Lu
President · +45,308 options
Insider 109,809 0.17% 2026-11-11
Anna Nijdam
Principal Accounting Officer · +22,670 options
Insider 46,275 0.07% 2026-06-04
Stefan Andreas Abele
Chief Technical Ops Officer · +44,500 options
Insider 39,068 0.06% 2026-09-15
Wim Souverijns
Chief Commercial Officer · +95,000 options
Insider 39,021 0.06% 2026-09-14
Elisabeth Bjork
Director · +11,000 options
Insider 15,167 0.02% 2026-09-17
Robert Glassman
Director
Insider 10,500 0.02% 2026-09-17
Viviane Monges
Director · +9,031 options
Insider 5,500 0.01% 2026-09-23

Share count 65,210,590 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PHVS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PHVS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.